Abstract:Introduction: Well-differentiated pancreatic neuroendocrine tumors (PNETs) can be non-functional or functional, e.g. insulinoma and glucagonoma. The majority of PNETs are sporadic, but PNETs also occur in hereditary syndromes, primarily multiple endocrine neoplasia type 1 (MEN1). The Knudson hypothesis stated a second, somatic hit in MEN1 as the cause of PNETs of MEN1 syndrome. In the recent years, reports on genetic somatic events in both sporadic and hereditary PNETs have emerged, providing a basis for a more detailed molecular understanding of the pathophysiology. In this systematic review and meta-analysis, we made a collation and statistical analysis of aggregated frequent genetic alterations and potential driver events in human grade G1/G2 PNETs. Methods: A systematic search was performed in concordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) reporting guidelines of 2020. A search in Pubmed for published studies using whole exome, whole genome, or targeted gene panel (+400 genes) sequencing of human G1/G2 PNETs was conducted at the 25 th of September 2023. Fourteen datasets from published studies were included with data on 221 patients and 225 G1/G2 PNETs, which were divided into sporadic tumors, and hereditary tumors with pre-disposing germline variants, and tumors with unknown germline status. Further, non-functioning and functioning PNETs were distinguished into two groups for pathway evaluation. The collated genetical analyses were conducted using the 'maftools' R-package. Results: Sporadic PNETs accounted 72.0% (162/225), hereditary PNETs 13.3% (30/225), unknown germline status 14.7% (33/225). The most frequently altered gene was MEN1 , with somatic variants and copy number variations in overall 42% (95/225); hereditary PNETs (germline variations in MEN1 , VHL , CHEK2 , BRCA2 , PTEN , CDKN1B , and/or MUTYH ) 57% (16/30); sporadic PNETs 36% (58/162); unknown germline status 64% (21/33). The MEN1 point mutations/indels were distributed throughout MEN1 . Overall, DAXX (16%, 37/225) and ATRX -variants (12%, 27/225) were also abundant with missense mutations clustered in mutational hotspots associated with histone binding, and translocase activity, respectively. DAXX mutations occurred more frequently in PNETs with MEN1 mutations, p<0.05. While functioning PNETs shared few variated genes, non-functioning PNETs had more recurrent variations in genes associated with the Phosphoinositide 3-kinase, Wnt, NOTCH, and Receptor Tyrosine Kinase-Ras signaling onco-pathways. Discussion: The somatic genetic alterations in G1/G2 PNETs are diverse, but with distinct differences between sporadic vs. hereditary, and functional vs. non-functional PNETs. Increased understanding of the genetic alterations may lead to identification of more drivers and driver hotspots in the tumorigenesis in well-differentiated PNETs, potentially giving a basis for the identification of new drug targets. (Funded by Novo Nordisk Foundation, grant number NNF19OC0057915).

Chromosomal Alteration Patterns in PitNETs: Massive Losses in Aggressive Tumors

Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors

Pangenomic Classification of Pituitary Neuroendocrine Tumors

Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways

Single-Cell Sequencing Identifies Cellular Origins and Differentiation Markers for Molecular Classification and Recurrence Prediction of PitnNET

Single-cell Transcriptome and Genome Analyses of Pituitary Neuroendocrine Tumors.

Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors

Tmic-02. Single-Cell High-Dimensional Mass Cytometry (Cytof) Reveals Immune Landscape Of Pituitary Neuroendocrine Tumors

High-Grade Progression, Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms (PitNENs): The UCSF Experience

Single-cell transcriptomics link gene expression signatures to clinicopathological features of gonadotroph and lactotroph PitNET

Single Cell Metabolic Landscape of Pituitary Neuroendocrine Tumor Subgroups and Lineages

Digital Image Analysis Allows Objective Stratification of Patients with Silent PIT1-lineage Pituitary Neuroendocrine Tumors.

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials

Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data

Whole-Genome Landscape of Pancreatic Neuroendocrine Tumours

High Throughput Gene Sequencing Reveals Altered Landscape in DNA Damage Responses and Chromatin Remodeling in Sporadic Pancreatic Neuroendocrine Tumors.

Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology

Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification

Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor

Practical approaches to diagnosing PitNETs/adenomas based on cell lineage

Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice